PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHOR	ORITY				
To: DAVID A. FARAH SHELDON & MAK PC		PCT			
225 SOUTH LAKE AVENUE 9TH FLOOR PASADENA, CA 91101			ITTEN OPINION OF THE ONAL SEARCHING AUTHORITY		
			(PCT Rule 43bis.1)		
		Date of mailing (day/month/year)	0 1 MAR 2005		
Applicant's or agent's file reference		FOR FURTHER ACTION See paragraph 2 below			
14399-1PCT International application No.	International filing date ((day/month/year)	Priority date (day/month/year)		
''					
PCT/US04/07434 10 March 2004 (10.03.2 International Patent Classification (IPC) or both national classification		ion and IPC	10 March 2003 (10.03.2003)		
69.1, 5, 6, 7.1; 514/2, 44; 530/350	56, 15/63, 15/64, 5/10; C0	07K 14/435; C12Q 1	1/68, 1/70 and US Cl.: 435/320.1, 455, 456,		
Applicant			•		
REGENTS OF THE UNIVERSITY OF	CALIFORNIA				
1. This opinion contains indications rela	ating to the following item	s:			
Box No. I Basis of the opinion					
Box No. II Priority					
Box No. III Non-establis	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
Box No. IV Lack of unit	Lack of unity of invention				
	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI Certain docu	Certain documents cited				
Box No. VII Certain defe	Certain defects in the international application				
Box No. VIII Certain observations on the international application					
2. FURTHER ACTION					
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.					
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.					
For further options, see Form PCT/ISA/220.					
3. For further details, see notes to Form	PCT/ISA/220.		2 2 2		
Name and mailing address of the ISA/ US		Authorized officer	Mary Was		
Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450		David Guzo	TT		
Alexandria, Virginia 22313-1450		Telephone No. (7	703) 308-0196		

Facsimile No. (703) 305-3230
Form PCT/ISA/237 (cover sheet) (January 2004)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/07434

Box No. I Basis of this opinion					
	regard to the language, this opinion has been established on the basis of the international application in the language in which s filed, unless otherwise indicated under this item.				
	This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).				
	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the ed invention, this opinion has been established on the basis of:				
a.	type of material				
	a sequence listing				
	table(s) related to the sequence listing				
b.	format of material				
	in written format				
	in computer readable form				
c.	time of filing/furnishing				
	contained in international application as filed.				
	filed together with the international application in computer readable form.				
	furnished subsequently to this Authority for the purposes of search.				
3. 🔀	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.				
4. Additional comments:					
	-				

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/07434

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims 1-5,9-35 and 39-66	YES
	Claims 6-8 and 36-38	NO
Inventive step (IS)	Claims 1-5,9-35 and 39-66	YES
•	Claims 6-8 and 36-38	NO
Industrial applicability (IA)	Claims <u>1-66</u>	YES
•	Claims NONE	NO

2. Citations and explanations:

Claims 6-8 and 36-38 lack novelty under PCT Article 33(2) as being anticipated by Suprenant or vanZon et al. Both Suprenant and vanZon et al. teach vault like particles (vaults) comprising the three natural components of vaults (MVP, VPARP and TEP1). With regard to the limitations of claims 37-38, it is noted that the recited portions of SEQ ID NO:3 read on the natural human VPARP protein which is well known in the art as disclosed and reviewed by Suprenant and vanZon et al.

Claims 1-5, 9-35 and 39-66 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the claimed vaults comprising modified vault proteins as well as the methods of using vaults as carriers to deliver substances to target cells, tissue or organisms or methods of detecting signals from sensors within a cell or organism or methods of making vault-like particles using bacmids and insect cells.

Claims 1-66 meet the criteria set out in PCT Article 33(4), and thus possess industrial applicability because the subject matter claimed can be made or used in industry. Specifically, the claimed vault-like particles can be used deliver pharmaceutical agents to target cells in an organism.

Form PCT/ISA/237 (Box No. V) (January 2004)

NOTESTO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file-amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended

During the international phase, the claims may also be amenced (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions. Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.